



September 22, 2014

Esperion Therapeutics to Present at BioCentury's NewsMakers in the Biotech Industry Conference

Webcast on Friday, September 26, 2014 at 8:30 a.m. Eastern Time

ANN ARBOR, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (NASDAQ: EPR) a clinical-stage emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced the Company will present at the BioCentury NewsMakers in the Biotech Industry Conference in New York City, N.Y. The presentation will take place on Friday, September 26 at 8:30 a.m. Eastern Time, when Tim M. Mayleben, president and chief executive officer, will provide an update on the company.

A live, listen-only webcast of the presentation can be accessed on the investor relations section of the Esperion website at www.esperion.com. A webcast replay of the presentation will be available approximately one hour after completion and will be archived on the Company's website for 90 days following the event.

Esperion's Commitment to Cardiometabolic Disease

Esperion is committed to improving the lives of patients with cardiometabolic diseases. The Esperion team leverages its understanding of, and experience with, key biological pathways to discover and develop innovative therapies for the treatment of patients with hypercholesterolemia who have uncontrolled cholesterol levels despite the use of currently available therapies. Esperion has assembled a portfolio of programs including one product candidate in late-stage clinical evaluation (ETC-1002) and two pre-clinical product candidates.

About Esperion Therapeutics

Esperion Therapeutics, Inc. is a clinical-stage emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, LDL-cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. ETC-1002, Esperion's lead product candidate, is a unique, first-in-class, orally available, once-daily small molecule designed to lower LDL-cholesterol levels and avoid the side effects associated with therapies currently available for lowering LDL-cholesterol. ETC-1002 is being developed primarily for patients with hypercholesterolemia and a history of statin intolerance. Phase 2b clinical trials for ETC-1002 are currently underway and build upon the successful and comprehensive Phase 1 and Phase 2a programs. For more information, please visit www.esperion.com and follow us on Twitter at <https://twitter.com/EsperionInc>.

Media Contact:
W2O Group
Elliot Fox, 212.257.6724
efox@w2ogroup.com

or
Investor Contact:
Westwicke Partners
Jordan Kohnstam, 443.450.4189
jordan.kohnstam@westwicke.com

Source: Esperion Therapeutics, Inc.

News Provided by Acquire Media